1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Dementia Treatment Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porte Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Dementia Treatment Market, by Dementia Type
8.1.1. Alzheimer Disease (AD)
8.1.1.1. Market Revenue and Forecast
8.1.2. Vascular Dementia (VaD)
8.1.2.1. Market Revenue and Forecast
8.1.3. Lewy Body Dementia (LBD)
8.1.3.1. Market Revenue and Forecast
8.1.4. Frontotemporal Dementia (FTD)
8.1.4.1. Market Revenue and Forecast
8.1.5. Mixed Dementia
8.1.5.1. Market Revenue and Forecast
9.1. Dementia Treatment Market, by Treatment Type
9.1.1. Pharmacological Therapies
9.1.1.1. Market Revenue and Forecast
9.1.2. Non-Pharmacological Interventions
9.1.2.1. Market Revenue and Forecast
9.1.3. Digital Therapeutics/Cognitive Training Apps
9.1.3.1. Market Revenue and Forecast
9.1.4. Behavioral & Caregiver Support Programs
9.1.4.1. Market Revenue and Forecast
9.1.5. Combination/Integrated Care
9.1.5.1. Market Revenue and Forecast
10.1. Dementia Treatment Market, by Product Type
10.1.1. Prescription Drugs
10.1.1.1. Market Revenue and Forecast
10.1.2. Over-the-Counter (OTC) Supplements
10.1.2.1. Market Revenue and Forecast
10.1.3. Medical Devices/Cognitive Support Tools
10.1.3.1. Market Revenue and Forecast
10.1.4. Digital Therapeutics/Software Platforms
10.1.4.1. Market Revenue and Forecast
10.1.5. Wearables & Monitoring Devices
10.1.5.1. Market Revenue and Forecast
11.1. Dementia Treatment Market, by End-User/Customer Segment
11.1.1. Hospitals & Neurology Clinics
11.1.1.1. Market Revenue and Forecast
11.1.2. Primary Care/Geriatric Care Centers
11.1.2.1. Market Revenue and Forecast
11.1.3. Home Care/Assisted Living Facilities
11.1.3.1. Market Revenue and Forecast
11.1.4. Pharmacies & Retail (OTC distribution)
11.1.4.1. Market Revenue and Forecast
11.1.5. Research Institutes/CROs
11.1.5.1. Market Revenue and Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Dementia Type
12.1.2. Market Revenue and Forecast, by Treatment Type
12.1.3. Market Revenue and Forecast, by Product Type
12.1.4. Market Revenue and Forecast, by End-User/Customer Segment
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Dementia Type
12.1.5.2. Market Revenue and Forecast, by Treatment Type
12.1.5.3. Market Revenue and Forecast, by Product Type
12.1.5.4. Market Revenue and Forecast, by End-User/Customer Segment
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Dementia Type
12.1.6.2. Market Revenue and Forecast, by Treatment Type
12.1.6.3. Market Revenue and Forecast, by Product Type
12.1.6.4. Market Revenue and Forecast, by End-User/Customer Segment
12.2. Europe
12.2.1. Market Revenue and Forecast, by Dementia Type
12.2.2. Market Revenue and Forecast, by Treatment Type
12.2.3. Market Revenue and Forecast, by Product Type
12.2.4. Market Revenue and Forecast, by End-User/Customer Segment
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Dementia Type
12.2.5.2. Market Revenue and Forecast, by Treatment Type
12.2.5.3. Market Revenue and Forecast, by Product Type
12.2.5.4. Market Revenue and Forecast, by End-User/Customer Segment
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Dementia Type
12.2.6.2. Market Revenue and Forecast, by Treatment Type
12.2.6.3. Market Revenue and Forecast, by Product Type
12.2.6.4. Market Revenue and Forecast, by End-User/Customer Segment
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Dementia Type
12.2.7.2. Market Revenue and Forecast, by Treatment Type
12.2.7.3. Market Revenue and Forecast, by Product Type
12.2.7.4. Market Revenue and Forecast, by End-User/Customer Segment
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Dementia Type
12.2.8.2. Market Revenue and Forecast, by Treatment Type
12.2.8.3. Market Revenue and Forecast, by Product Type
12.2.8.4. Market Revenue and Forecast, by End-User/Customer Segment
12.3. APAC
12.3.1. Market Revenue and Forecast, by Dementia Type
12.3.2. Market Revenue and Forecast, by Treatment Type
12.3.3. Market Revenue and Forecast, by Product Type
12.3.4. Market Revenue and Forecast, by End-User/Customer Segment
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Dementia Type
12.3.5.2. Market Revenue and Forecast, by Treatment Type
12.3.5.3. Market Revenue and Forecast, by Product Type
12.3.5.4. Market Revenue and Forecast, by End-User/Customer Segment
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Dementia Type
12.3.6.2. Market Revenue and Forecast, by Treatment Type
12.3.6.3. Market Revenue and Forecast, by Product Type
12.3.6.4. Market Revenue and Forecast, by End-User/Customer Segment
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Dementia Type
12.3.7.2. Market Revenue and Forecast, by Treatment Type
12.3.7.3. Market Revenue and Forecast, by Product Type
12.3.7.4. Market Revenue and Forecast, by End-User/Customer Segment
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Dementia Type
12.3.8.2. Market Revenue and Forecast, by Treatment Type
12.3.8.3. Market Revenue and Forecast, by Product Type
12.3.8.4. Market Revenue and Forecast, by End-User/Customer Segment
12.4. MEA
12.4.1. Market Revenue and Forecast, by Dementia Type
12.4.2. Market Revenue and Forecast, by Treatment Type
12.4.3. Market Revenue and Forecast, by Product Type
12.4.4. Market Revenue and Forecast, by End-User/Customer Segment
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Dementia Type
12.4.5.2. Market Revenue and Forecast, by Treatment Type
12.4.5.3. Market Revenue and Forecast, by Product Type
12.4.5.4. Market Revenue and Forecast, by End-User/Customer Segment
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Dementia Type
12.4.6.2. Market Revenue and Forecast, by Treatment Type
12.4.6.3. Market Revenue and Forecast, by Product Type
12.4.6.4. Market Revenue and Forecast, by End-User/Customer Segment
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Dementia Type
12.4.7.2. Market Revenue and Forecast, by Treatment Type
12.4.7.3. Market Revenue and Forecast, by Product Type
12.4.7.4. Market Revenue and Forecast, by End-User/Customer Segment
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Dementia Type
12.4.8.2. Market Revenue and Forecast, by Treatment Type
12.4.8.3. Market Revenue and Forecast, by Product Type
12.4.8.4. Market Revenue and Forecast, by End-User/Customer Segment
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Dementia Type
12.5.2. Market Revenue and Forecast, by Treatment Type
12.5.3. Market Revenue and Forecast, by Product Type
12.5.4. Market Revenue and Forecast, by End-User/Customer Segment
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Dementia Type
12.5.5.2. Market Revenue and Forecast, by Treatment Type
12.5.5.3. Market Revenue and Forecast, by Product Type
12.5.5.4. Market Revenue and Forecast, by End-User/Customer Segment
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Dementia Type
12.5.6.2. Market Revenue and Forecast, by Treatment Type
12.5.6.3. Market Revenue and Forecast, by Product Type
12.5.6.4. Market Revenue and Forecast, by End-User/Customer Segment
13.1. Biogen Inc
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Eli Lilly and Company
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Roche Holding AG
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Novartis AG
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Eisai Co., Ltd
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Johnson & Johnson
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Pfizer Inc
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Merck & Co., Inc
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Takeda Pharmaceutical Company Limited
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. AbbVie Inc
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
